Should You Consider Adding Guardian Pharmacy Services (GRDN) to Your Portfolio?

By Soumya Eswaran | July 23, 2025, 8:28 AM

Aristotle Capital Boston, LLC, an investment advisor, released its “Small Cap Equity Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter started with a risk-off environment from the previous quarter, but later regained momentum driven by broad-based elements. In the second quarter, the strategy delivered a return of 3.25% net of fees (3.41% gross of fees) underperforming the 8.50% total return of the Russell 2000 Index. For more information on the fund’s best picks in 2025, please check its top five holdings.

In its second quarter 2025 investor letter, Aristotle Capital Small Cap Equity Strategy highlighted stocks such as Guardian Pharmacy Services, Inc. (NYSE:GRDN). Headquartered in Atlanta, Georgia, Guardian Pharmacy Services, Inc. (NYSE:GRDN) is a pharmacy service company. The one-month return of Guardian Pharmacy Services, Inc. (NYSE:GRDN) was 0.10%, and YTD its shares gained 0.35% of their value. On July 22, 2025, Guardian Pharmacy Services, Inc. (NYSE:GRDN) stock closed at $20.33 per share, with a market capitalization of $1.287 billion.

Aristotle Capital Small Cap Equity Strategy stated the following regarding Guardian Pharmacy Services, Inc. (NYSE:GRDN) in its second quarter 2025 investor letter:

"Guardian Pharmacy Services, Inc. (NYSE:GRDN), is a leading provider of pharmacy services to long-term care assisted living and behavioral health facilities in the U.S. The company has built a market leading position as a result of a differentiated technology-driven service offering that benefits patients, facility operators and payors. We believe the company is well positioned to continue to capitalize on the secular trend of the aging U.S. population and grow faster than the overall market because of their specific service offering."

Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors?
A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases.

Guardian Pharmacy Services, Inc. (NYSE:GRDN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 9 hedge fund portfolios held Guardian Pharmacy Services, Inc. (NYSE:GRDN) at the end of the first quarter, which was 8 in the previous quarter. While we acknowledge the potential of Guardian Pharmacy Services, Inc. (NYSE:GRDN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.

Latest News

Aug-25
Aug-11
Aug-11
Aug-04
Jul-23
Jul-22
Jun-10
Jun-02
May-22
May-20
May-14
May-13
May-12
May-12
May-08